Glucose B Braun

Glucose B Braun is a sterile aqueous solution for injection that contains glucose as the sole active ingredient. It is supplied in an unspecified concentration and is classified as an excipient/carbohydrate solution used in parenteral nutrition and fluid replacement. The product is marketed in the European Union and is available by prescription only for intravenous administration. It is intended for use in hospital settings to provide an immediate source of energy and to assist in maintaining osmotic balance during intravenous therapy.

Glucose B Braun is employed in clinical practice for several intravenous indications related to energy provision and fluid management.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens to meet carbohydrate requirements. - Fluid and electrolyte replacement in patients unable to tolerate oral intake. - Diluent for the preparation of other intravenous medications. - Support of osmotic balance during renal replacement therapy. - Adjunct in emergency resuscitation protocols to quickly restore blood glucose levels.

When administered intravenously, Glucose B Braun may be associated with a range of physiological responses, some of which are expected and others that require clinical attention.

Common: - Transient hyperglycemia, especially in patients with impaired insulin response. - Mild electrolyte shifts, such as slight decreases in serum potassium. - Local irritation at the infusion site if the solution is hyperosmolar. - Fluid overload in patients receiving large volumes. - Slight increase in serum osmolality, usually clinically insignificant.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hyperosmolar hyperglycemic state (HHS) in susceptible individuals. - Allergic reactions ranging from urticaria to anaphylaxis. - Metabolic acidosis if administered in excess without appropriate monitoring. - Intravenous extravasation causing tissue injury if administered improperly.

Clinicians should observe specific precautions when prescribing Glucose B Braun to ensure patient safety and optimal therapeutic outcomes.

- Verify blood glucose levels before and during infusion to avoid hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Monitor electrolyte concentrations, particularly potassium and sodium, during therapy. - Use aseptic technique to prevent contamination of the sterile solution. - Assess for signs of allergic reaction, especially in patients with a history of carbohydrate hypersensitivity. - Avoid rapid bolus administration unless clinically indicated. - Document the concentration and total volume administered in the patient record.

Glucose B Braun may interact with other intravenous agents or systemic conditions, requiring careful consideration of concurrent therapies.

Avoid: - Co-administration with high‑dose insulin infusions without glucose monitoring, which can precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic saline solutions that may exacerbate hyperosmolar states. - Mixing with calcium-containing solutions can cause precipitation; administer separately.

Use with caution: - Concurrent use of potassium‑sparing diuretics; monitor serum potassium closely. - Administration alongside other carbohydrate‑containing parenteral solutions; adjust total carbohydrate load. - Patients receiving total parenteral nutrition; balance glucose infusion rates to avoid excess calories. - Use in patients with renal failure; monitor fluid balance and electrolytes.